Physician profile
Brian A Sumner
NPI 1528048550
$2,258.84
in general payments reported to CMS, 2019-2025
26 companies · $460 in 2025
The $460 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $285 · 2021: $170 · 2022: $269 · 2023: $272 · 2024: $394 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $457.48 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Cranial Technologies, INC | $243.91 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $227.63 | 2019-2025 | Bexsero, Pediarix |
| Sanofi-Aventis U.S. LLC | $184.17 | 2023-2025 | |
| Kaleo, INC. | $151.06 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $150.75 | 2019-2024 | |
| Abiomed | $146.08 | 2025 | |
| Ironshore Pharmaceuticals INC. | $123.97 | 2019-2024 | |
| Corium, LLC | $95.23 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $92.61 | 2022-2023 | Vaxneuvance, M-M-R II, Proquad |
| Supernus Pharmaceuticals, INC. | $63.36 | 2021-2025 | Qelbree |
| Alk-Abello, INC | $36.88 | 2023-2025 | Neffy, Ragwitek, Odactra |
| Acadia Pharmaceuticals INC | $35.86 | 2023-2024 | Daybue |
| Collegium Pharmaceutical, INC. | $35.56 | 2025 | Jornay Pm |
| Biomarin Pharmaceutical INC. | $32.75 | 2023-2025 | Voxzogo 1.2mg |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $29.32 | 2019 | |
| Neos Therapeutics, LP | $22.62 | 2019 | |
| Aytu Biopharma, INC. | $17.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.60 | 2024 | Xarelto |
| Genentech USA, INC. | $14.90 | 2019 | |
| Adlon Therapeutics L.P. | $14.89 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.87 | 2024 | Ycanth |
| Novartis Pharmaceuticals Corporation | $13.13 | 2019 | |
| Biogen, INC. | $12.68 | 2021 | |
| Sobi, INC | $12.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.